Abstract 323P
Background
Ovarian cancer is a general phrase that may be applied to any malignancy that affects the ovaries and is one of the worst malignancies. Aside from the number of its population, the Asian population also has a very diverse culture and socioeconomic development. Pretreatment peripheral blood cell counts, including lymphocytes, monocytes, and neutrophils, are major prognostic indicators in various cancers. This study aimed to evaluate the role of NLR, PLR, and LMR as prognostic biomarkers in ovarian cancer among the Asian population in a meta-analysis design.
Methods
This study assessed the association between NLR, PLR, and LMR and ovarian cancer as prognostic biomarkers based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The literature research was performed by systematically searching PubMed, ScienceDirect, and Google Scholar using the search terms based on BOOLEAN operators. Revman software ver 5.4.1 was employed for all statistical analyses, and p-values<0.05 were considered statistically significant.
Results
This study included 17 studies conducted in various Asian countries according to inclusion and exclusion criteria. Significant results were found in both univariate and multivariate analysis for NLR, PLR, and LMR to overall survival [(Univariate) NLR: HR 2.04; 95% CI 1.61 – 2.58; p<0.001, PLR: HR 2.04; 95% CI 1.26 – 3.30; p<0.001, LMR: HR 0.53; 95% CI 0.40 – 0.72; p<0.001. (Multivariate) NLR: HR 1.65; 95% CI 1.22 – 2.22; p<0.001, PLR: HR 2.12; 95% CI 1.70 – 2.66; p<0.001, LMR: HR 0.54; 95% CI 0.37 – 0.80; p=0.002]. Significant results were also found in both univariate and multivariate analysis for NLR and PLR to disease-free survival [(Univariate) NLR: HR 2.19; 95% CI 1.36 – 3.54; p<0.001, PLR: HR 1.95; 95% CI 1.31 – 2.91; p<0.001. (Multivariate) NLR: HR 1.37; 95% CI 1.21 – 1.56; p<0.001, PLR: HR 1.78; 95% CI 1.45 – 2.17; p<0.001.
Conclusions
NLR, PLR, and LMR can be considered as prognostic biomarkers in ovarian cancer. Further studies are needed to re-evaluate these findings in the Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.G.P. Supadmanaba.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract